Systematic evaluation of clinical practice guidelines for pharmacogenomics

To systematically assess methodological quality of pharmacogenomics clinical practice guidelines. Guidelines published through 2017 were reviewed by at least three independent reviewers using the AGREE II instrument, which consists of 23 items grouped into 6 domains and 2 items representing an overa...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2018-06, Vol.19 (8), p.693-700
Main Authors: Beckett, Robert D, Kisor, David F, Smith, Thomas, Vonada, Brooke
Format: Article
Language:English
Subjects:
AGREE II
Chemotherapy
Clinical medicine
Clinical practice guidelines
Collaboration
Consortia
Decision making
Drug dosages
Evidence-Based Medicine - standards
evidence-based practice
Fractures
Genomes
Health care
Humans
Oncology
Pharmacists
Pharmacogenetics - standards
Pharmacogenomics
Quality
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c371t-456d4f82b0f217cb8e6a4586c01515aefb1940899d176f516fb58b2aea7800aa3
cites cdi_FETCH-LOGICAL-c371t-456d4f82b0f217cb8e6a4586c01515aefb1940899d176f516fb58b2aea7800aa3
container_end_page 700
container_issue 8
container_start_page 693
container_title Pharmacogenomics
container_volume 19
creator Beckett, Robert D
Kisor, David F
Smith, Thomas
Vonada, Brooke
description To systematically assess methodological quality of pharmacogenomics clinical practice guidelines. Guidelines published through 2017 were reviewed by at least three independent reviewers using the AGREE II instrument, which consists of 23 items grouped into 6 domains and 2 items representing an overall assessment. Items were assessed on a 7-point rating scale, and aggregate quality scores were calculated. Thirty-one articles were included. All guidelines were published as peer-reviewed articles and 90% (n = 28) were endorsed by professional organizations. Mean AGREE II domain scores (maximum score 100%) ranged from 46.6 ± 11.5% ('applicability') to 78.9 ± 11.4% ('Clarity of Presentation'). Median overall quality score was 72.2% (IQR: 61.1-77.8%). Quality of pharmacogenomics guidelines was generally high, but variable, for most AGREE II domains.
doi_str_mv 10.2217/pgs-2018-0024
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2043172552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2043172552</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-456d4f82b0f217cb8e6a4586c01515aefb1940899d176f516fb58b2aea7800aa3</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMo7rp69CoFL16qSZom7VEWP1nwoJ5Dmk7WLG1Tk1bYf2-Wrh4ET5nMPPMyPAidE3xNKRE3_TqkFJMixZiyAzQngrG0wIwexppxmlJG-AydhLCJBOEMH6MZLUWJGRFz9Py6DQO0arA6gS_VjLFyXeJMohvbWa2apPdKxzEk69HWELsQEuN80n8o3yrt1tC51upwio6MagKc7d8Fer-_e1s-pquXh6fl7SrVmSBDynJeM1PQCpt4v64K4IrlBdeY5CRXYCpSMlyUZU0ENznhpsqLiipQosBYqWyBrqbc3rvPEcIgWxs0NI3qwI1BUswyImie04he_kE3bvRdvE7SjPIyE1FapNKJ0t6F4MHI3ttW-a0kWO4kyyhZ7iRLPPEX-9SxaqH-pX-sRqCcADMOo4egLXQa5PSLG1ZHif-EfwMPt4r1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2326937024</pqid></control><display><type>article</type><title>Systematic evaluation of clinical practice guidelines for pharmacogenomics</title><source>PubMed (Medline)</source><creator>Beckett, Robert D ; Kisor, David F ; Smith, Thomas ; Vonada, Brooke</creator><creatorcontrib>Beckett, Robert D ; Kisor, David F ; Smith, Thomas ; Vonada, Brooke</creatorcontrib><description>To systematically assess methodological quality of pharmacogenomics clinical practice guidelines. Guidelines published through 2017 were reviewed by at least three independent reviewers using the AGREE II instrument, which consists of 23 items grouped into 6 domains and 2 items representing an overall assessment. Items were assessed on a 7-point rating scale, and aggregate quality scores were calculated. Thirty-one articles were included. All guidelines were published as peer-reviewed articles and 90% (n = 28) were endorsed by professional organizations. Mean AGREE II domain scores (maximum score 100%) ranged from 46.6 ± 11.5% ('applicability') to 78.9 ± 11.4% ('Clarity of Presentation'). Median overall quality score was 72.2% (IQR: 61.1-77.8%). Quality of pharmacogenomics guidelines was generally high, but variable, for most AGREE II domains.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs-2018-0024</identifier><identifier>PMID: 29790417</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>AGREE II ; Chemotherapy ; Clinical medicine ; Clinical practice guidelines ; Collaboration ; Consortia ; Decision making ; Drug dosages ; Evidence-Based Medicine - standards ; evidence-based practice ; Fractures ; Genomes ; Health care ; Humans ; Oncology ; Pharmacists ; Pharmacogenetics - standards ; Pharmacogenomics ; Quality ; Reviews</subject><ispartof>Pharmacogenomics, 2018-06, Vol.19 (8), p.693-700</ispartof><rights>2018 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Jun 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-456d4f82b0f217cb8e6a4586c01515aefb1940899d176f516fb58b2aea7800aa3</citedby><cites>FETCH-LOGICAL-c371t-456d4f82b0f217cb8e6a4586c01515aefb1940899d176f516fb58b2aea7800aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29790417$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beckett, Robert D</creatorcontrib><creatorcontrib>Kisor, David F</creatorcontrib><creatorcontrib>Smith, Thomas</creatorcontrib><creatorcontrib>Vonada, Brooke</creatorcontrib><title>Systematic evaluation of clinical practice guidelines for pharmacogenomics</title><title>Pharmacogenomics</title><addtitle>Pharmacogenomics</addtitle><description>To systematically assess methodological quality of pharmacogenomics clinical practice guidelines. Guidelines published through 2017 were reviewed by at least three independent reviewers using the AGREE II instrument, which consists of 23 items grouped into 6 domains and 2 items representing an overall assessment. Items were assessed on a 7-point rating scale, and aggregate quality scores were calculated. Thirty-one articles were included. All guidelines were published as peer-reviewed articles and 90% (n = 28) were endorsed by professional organizations. Mean AGREE II domain scores (maximum score 100%) ranged from 46.6 ± 11.5% ('applicability') to 78.9 ± 11.4% ('Clarity of Presentation'). Median overall quality score was 72.2% (IQR: 61.1-77.8%). Quality of pharmacogenomics guidelines was generally high, but variable, for most AGREE II domains.</description><subject>AGREE II</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Clinical practice guidelines</subject><subject>Collaboration</subject><subject>Consortia</subject><subject>Decision making</subject><subject>Drug dosages</subject><subject>Evidence-Based Medicine - standards</subject><subject>evidence-based practice</subject><subject>Fractures</subject><subject>Genomes</subject><subject>Health care</subject><subject>Humans</subject><subject>Oncology</subject><subject>Pharmacists</subject><subject>Pharmacogenetics - standards</subject><subject>Pharmacogenomics</subject><subject>Quality</subject><subject>Reviews</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LxDAQhoMo7rp69CoFL16qSZom7VEWP1nwoJ5Dmk7WLG1Tk1bYf2-Wrh4ET5nMPPMyPAidE3xNKRE3_TqkFJMixZiyAzQngrG0wIwexppxmlJG-AydhLCJBOEMH6MZLUWJGRFz9Py6DQO0arA6gS_VjLFyXeJMohvbWa2apPdKxzEk69HWELsQEuN80n8o3yrt1tC51upwio6MagKc7d8Fer-_e1s-pquXh6fl7SrVmSBDynJeM1PQCpt4v64K4IrlBdeY5CRXYCpSMlyUZU0ENznhpsqLiipQosBYqWyBrqbc3rvPEcIgWxs0NI3qwI1BUswyImie04he_kE3bvRdvE7SjPIyE1FapNKJ0t6F4MHI3ttW-a0kWO4kyyhZ7iRLPPEX-9SxaqH-pX-sRqCcADMOo4egLXQa5PSLG1ZHif-EfwMPt4r1</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Beckett, Robert D</creator><creator>Kisor, David F</creator><creator>Smith, Thomas</creator><creator>Vonada, Brooke</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180601</creationdate><title>Systematic evaluation of clinical practice guidelines for pharmacogenomics</title><author>Beckett, Robert D ; Kisor, David F ; Smith, Thomas ; Vonada, Brooke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-456d4f82b0f217cb8e6a4586c01515aefb1940899d176f516fb58b2aea7800aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>AGREE II</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Clinical practice guidelines</topic><topic>Collaboration</topic><topic>Consortia</topic><topic>Decision making</topic><topic>Drug dosages</topic><topic>Evidence-Based Medicine - standards</topic><topic>evidence-based practice</topic><topic>Fractures</topic><topic>Genomes</topic><topic>Health care</topic><topic>Humans</topic><topic>Oncology</topic><topic>Pharmacists</topic><topic>Pharmacogenetics - standards</topic><topic>Pharmacogenomics</topic><topic>Quality</topic><topic>Reviews</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beckett, Robert D</creatorcontrib><creatorcontrib>Kisor, David F</creatorcontrib><creatorcontrib>Smith, Thomas</creatorcontrib><creatorcontrib>Vonada, Brooke</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest UK &amp; Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beckett, Robert D</au><au>Kisor, David F</au><au>Smith, Thomas</au><au>Vonada, Brooke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systematic evaluation of clinical practice guidelines for pharmacogenomics</atitle><jtitle>Pharmacogenomics</jtitle><addtitle>Pharmacogenomics</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>19</volume><issue>8</issue><spage>693</spage><epage>700</epage><pages>693-700</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>To systematically assess methodological quality of pharmacogenomics clinical practice guidelines. Guidelines published through 2017 were reviewed by at least three independent reviewers using the AGREE II instrument, which consists of 23 items grouped into 6 domains and 2 items representing an overall assessment. Items were assessed on a 7-point rating scale, and aggregate quality scores were calculated. Thirty-one articles were included. All guidelines were published as peer-reviewed articles and 90% (n = 28) were endorsed by professional organizations. Mean AGREE II domain scores (maximum score 100%) ranged from 46.6 ± 11.5% ('applicability') to 78.9 ± 11.4% ('Clarity of Presentation'). Median overall quality score was 72.2% (IQR: 61.1-77.8%). Quality of pharmacogenomics guidelines was generally high, but variable, for most AGREE II domains.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>29790417</pmid><doi>10.2217/pgs-2018-0024</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1462-2416
ispartof Pharmacogenomics, 2018-06, Vol.19 (8), p.693-700
issn 1462-2416
1744-8042
language eng
recordid cdi_proquest_miscellaneous_2043172552
source PubMed (Medline)
subjects AGREE II
Chemotherapy
Clinical medicine
Clinical practice guidelines
Collaboration
Consortia
Decision making
Drug dosages
Evidence-Based Medicine - standards
evidence-based practice
Fractures
Genomes
Health care
Humans
Oncology
Pharmacists
Pharmacogenetics - standards
Pharmacogenomics
Quality
Reviews
title Systematic evaluation of clinical practice guidelines for pharmacogenomics
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T20%3A35%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systematic%20evaluation%20of%20clinical%20practice%20guidelines%20for%20pharmacogenomics&rft.jtitle=Pharmacogenomics&rft.au=Beckett,%20Robert%20D&rft.date=2018-06-01&rft.volume=19&rft.issue=8&rft.spage=693&rft.epage=700&rft.pages=693-700&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs-2018-0024&rft_dat=%3Cproquest_cross%3E2043172552%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c371t-456d4f82b0f217cb8e6a4586c01515aefb1940899d176f516fb58b2aea7800aa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2326937024&rft_id=info:pmid/29790417&rfr_iscdi=true